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Endothelin-1 (ET-1) predominates in the endothelin family effectively in vascular tone control, mitogenesis, and neuromodulation.
Its receptors are widespread in the central nervous system (CNS) associated with endogenous pain control, suggesting an important
role of ET-1 in central pain processing. This study aimed to evaluate the effect of central ET-1 on the development of neuropathic
pain behaviour by repeated intrathecal administration of endothelin type A receptor (ETAR) antagonist (BQ-123) in a sciatic nerve
ligation (SNL) animal model. BQ-123 was administered intrathecally to rats at dosages 15𝜇g, 20𝜇g, 25 𝜇g, and 30 𝜇g, daily for 3
days. Mechanical allodynia was assessed daily 30minutes before/after injection, 1 hour after injection of BQ-123 from post-SNL day
4 to day 6, and once on day 7 (without BQ-123 administration) before rats were sacrificed. Increasing trends ofmechanical threshold
were observed, and they reached significance at all dosages on post-SNL day 7 (𝑃 < 0.05 at dosage 15𝜇g and 𝑃 < 0.001 at dosages
20 𝜇g, 25𝜇g, and 30𝜇g) in comparison to control group. BQ-123 at dosage 30 𝜇g showed the most stable and significant mechanical
threshold rise. Repeated central administration of BQ-123 alleviated mechanical allodynia after SNL. Our results provide insight
into the therapeutic strategies, including timing, against neuropathic pain development with ETAR antagonist.
1. Introduction
The endothelin family majors in control of vascular tone and
is also involved in a large variety of pain processes as a neu-
romodulator. It consists of three peptides: ET-1, endothelin-2
(ET-2), and endothelin-3 (ET-3) and twomajor receptor sub-
types: endothelin type A receptor (ETAR) and endothelin
type B receptor (ETBR). ET-1 is the predominant and most
potent one among the three peptides and has higher binding
affinity towards the ETAR. ET-1 and its two receptor subtypes
are expressed at all levels of the nervous system [1, 2]. It is
a neurotransmitter/modulator in addition to its vasoactive
function in all mammalian species [3, 4]. The fact that
endothelin receptors are widespread in the areas associated
with endogenous pain control suggests that ET-1 may play a
role in cortical pain processing [5]. In previous studies, ET-1
has been shown to be antinociceptive in the central nervous
system (CNS) in contrast to its pronociceptive action in the
periphery [6–9]. Direct application of ET-1 to the peripheral
nervous system (PNS), such as subcutaneous injection, has
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been shown to elicit spontaneous pain or hyperalgesia in
both animals and humans [10, 11], and local intervention with
its receptor antagonists can abolish the overt nociceptive
behaviour [12, 13]. In contrast, intrathecal administration of
ET-1 was shown to suppress formalin-induced flinching
behaviour in rats [14]. In a thermal pain model, the anti-
nociceptive action of centrally injected ET-1 was blocked by
an ETAR antagonist which suggests that antinociception of
ET-1 in the CNS is mediated via ETAR [8].
Nevertheless, the effect of endogenous central ET-1 in the
development of neuropathic pain remains unclear. Although
most of the studies that have been done so far showed an anal-
gesic effect of ET-1 in the CNS, it is unknown how endoge-
nous ET-1 contributes to neuropathic pain because the above-
mentioned studies were done using either animal inflam-
matory pain models or thermal pain tests to study the pain
response after central administration of ET-1 with or with-
out its receptor antagonists [14, 15]; moreover, exogenously
injected ET-1 is an extra boost to the CNS that its effect may
not represent the influence of endogenous level of ET-1 under
pathological condition. In fact, there were only a few studies
that related ET-1 to neuropathic pain, but they focused
on periphery which demonstrated antiallodynic effects of
ETAR/ETBR antagonists in the PNS [16, 17].Thus, it would be
interesting to test whether exogenous administration of only
ET-1 receptor antagonists in the CNS would have analgesic
effect in neuropathic pain or not. Since the contribution of
central endogenous ET-1 to the development of neuropathic
pain has not been adequately studied, we aim to investigate
this subject by examining the effect of repeated intrathecal
administration of an ETAR antagonist, BQ-123, on sciatic
nerve ligation- (SNL-) induced neuropathic pain.
2. Materials and Methods
2.1. Animals. Animal experiments were conducted according
to the US National Institute of Health Guide for the Care and
Use of Laboratory Animals and were approved by the Com-
mittee on the Use of Live Animals in Teaching and Research
from The University of Hong Kong. Adult male Sprague-
Dawley (SD) rats (250∼300 g) were used in this experiment.
Rats were kept individually in plastic cages with a floor cov-
ered with soft bedding at room temperature and were main-
tained on a light/dark cycle of 12 hours day/night. Food and
water were provided ad libitum.
2.2. Sciatic Nerve Ligation Model. A sciatic nerve ligation
(SNL) model using male, adult, SD rats was adopted in this
study. The surgical technique for the right sciatic nerve was
performed according to the method described by Seltzer et
al. [18]. Animals were anesthetized with sodium pentobarbi-
tal 70mg/kg administrated intraperitoneally. Under aseptic
condition, an incision from the right sciatic notch to the distal
thigh was made after the animal lost response to tail and toe
pinch. After exposure of the sciatic nerve, a ligature about
one-third to one-half the diameter of the sciatic nerve was
made to the nerve with 7–0 silicon-treated silk suture. The
wound was then closed with 2 to 3 skin sutures (4–0 cotton).
In sham-operated animals, the sciatic nerve was exposed in
the same manner but not ligated.
2.3. Catheter Implantation. After SNL surgery, catheter
implantation was performed. Polyethylene tube PE-10 (Clay
Adams, USA) was implanted using a lumbar approach
according to the method described [19]. An incision was
made along the spinal cord at the pelvic girdle region, and
a saline-filled sterile PE-10 tube catheter was inserted into
the intervertebral space between vertebrae L5 and L6. The
inserted part of the catheter was about 2 cm so it could reach
the lumbar enlargement of the spinal cord. Correct intrathe-
cal insertion was noted by a tail-flick or a twitch in the hind
paw. Then the catheter was tunnelled rostrally under skin
with a guide-cannula towards the occipital region to allow
about 4 cm catheter appear to in the region for drug infusion.
Ten microlitres of sterile saline was injected to flush and fill
the catheter, and the end of the indwelling catheter was then
sealed bymelting it.Thewoundwas closed with 3 to 4 sutures
(4–0 cotton). The animals were then allowed to recover for 3
days after the surgery. Any rats with neurologic deficit due to
the surgical procedure were excluded from the experiment.
2.4. Study Drug BQ-123 Administration. BQ-123 (Calbio-
chem, USA) at four dosages 15 𝜇g, 20𝜇g, 25 𝜇g, and 30 𝜇g
were each dissolved in sterile saline and administrated
intrathecally in a bolus of 10 𝜇L based on its usage in other
pain-related studies [20, 21]. Animals were randomly
assigned into six study groups as follows: (1) Sham group:
Sham-operated (no ligature placement on sciatic nerve)
animals treated with sterile saline (𝑛 = 6); (2) Control group:
SNL-operated animals treated with sterile saline (𝑛 = 6);
(3) Four BQ-123 drug groups: each group of SNL-operated
animalswere assigned to receive one of the four dosages 15𝜇g,
20𝜇g, 25 𝜇g, and 30 𝜇g (𝑛 = 6).
2.5. Mechanical Allodynia Assessment. Mechanical threshold
was assessed by testing the right hind paw withdrawal
response to Von Frey probe of the Electrovonfrey apparatus
(IITC/Life Science, Inc., USA). A transparent plastic dome
with a metal mesh floor was used to hold the animal during
assessment. Each animal was placed in the dome to allow
access to the plantar surface of the hind paw through the
metal mesh floor and allowed to accommodate to the envi-
ronment for 30 minutes before testing. During the test, a Von
Frey probe was pressed perpendicularly against the plantar
surface of the hind paw with continuous force. A positive
response was considered if the animal withdrew its hind paw
within 6 to 8 seconds except any hind pawmovements due to
locomotion. If no response was observed, a stiffer probe was
used until a response was observed. The force (in grams) to
elicit such positive response was shown on the screen of the
Electrovonfrey apparatus and recorded. The range of probe
we used in this study was from 10 g to 17 g according to
suggestions from a previous study [22].The test was repeated
three times for each rat at approximately 5-minute intervals,
and the mean values of the three repetitions were counted as
the mechanical threshold. The behavioural data were col-
lected before surgery on day 0 (surgery day) for baseline and
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Figure 1: Effect of BQ-123 (15𝜇g, 20𝜇g, 25𝜇g, and 30𝜇g) on
mechanical allodynia induced by sciatic nerve ligation (SNL) at
30 minutes after intrathecal administration. Drug administration
started on day 4 and continued to day 6 after SNL for 3 consecutive
days. Data presented asmean± S.E.M and 𝑛 = 6/group. Significance
is presented as ∗∗𝑃 < 0.01 for BQ-123 20 𝜇g group versus control
group; #𝑃 < 0.05 and ###𝑃 < 0.001 for BQ-123 25 𝜇g group versus
control group; +++𝑃 < 0.001 for BQ-123 30𝜇g group versus control
group.
at three time points each day from day 4 to day 6: 30 minutes
before injection, 30 minutes after injection, and 1 hour after
injection. Only a single time point, before injection, was
collected on day 7 as no drug was administered. All animals
were sacrificed on day 7 after SNL after behaviour test.
2.6. Statistics. All behavioural data were presented as mean ±
S.E.M. One-way analysis of variance (ANOVA) with Tukey’s
multiple comparison posttest was used for comparison of
different groups at one time point. Two-way ANOVA with
Bonferroni multiple comparisons posttest was used for com-
parison between different groups at multiple time points. 𝑃
value of <0.05 was considered significant.
3. Results
The present study examined the effect of ETAR antagonist in
the CNS on the development of SNL-induced neuropathic
pain by treating SNL-operated rat with a daily intrathecal
injection of BQ-123 at days 4, 5, and 6 after surgery. Adminis-
tration dosage of BQ-123 ranged between 15 𝜇g, 20𝜇g, 25 𝜇g,
and 30 𝜇g. We recorded mechanical thresholds of animals at
30minutes (Figure 1) or 1 hour (Figure 2) after administration
of BQ-123 or 30 minutes prior to administration at post-
SNL days 4, 5, and 6 (Figure 3) as well as day 7 which was
24 hours after the last injection of BQ-123 (Figure 3). We
observed significant decrease in mechanical thresholds in
all SNL-operated groups (control and drug groups) when
compared to sham group throughout the time course of
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Figure 2: Comparison of mechanical threshold between BQ-123
treatment groups (15𝜇g, 20𝜇g, 25𝜇g, and 30 𝜇g) and control group
at 1 hour after intrathecal administration. Drug administration
initiated on day 4 and continued to day 6 after sciatic nerve ligation
(SNL) for 3 consecutive days. Data are presented as mean ± S.E.M
and 𝑛 = 6/group. Significance is presented as ∗𝑃 < 0.05 for BQ-123
20 𝜇g group versus control group; #𝑃 < 0.05 and ##𝑃 < 0.01 for BQ-
123 25 𝜇g group versus control group; ++𝑃 < 0.01 and +++𝑃 < 0.001
for BQ-123 30 𝜇g group versus control group.
experiment (Figures 1, 2, and 3, all 𝑃 < 0.001). Sham
group did not show any significant change of mechanical
threshold to Von Frey stimulation throughout the study.
After intrathecal administration of BQ-123, elevated trends of
mechanical thresholds were seen in all BQ-123 drug groups as
shown in Figures 1, 2, and 3.
3.1. BQ-123 Group at Dose of 15𝜇g. BQ-123 at dose of 15 𝜇g
induced slight elevation of threshold when compared to the
control group 30 minutes and 1 hour after intrathecal admin-
istration of BQ-123 on day 4 to day 6, but the results were
not statistically significant (Figures 1 and 2). Significant anti-
allodynic effect was observed on post-SNL day 7 compared
with control group (Figure 3, 𝑃 < 0.05).
3.2. BQ-123 Group at Dose of 20 𝜇g. BQ-123 at dose of
20𝜇g produced significant antiallodynic effect both at 30
minutes and 1 hour after intrathecal drug administration. On
days 5 and 6, significant increase of mechanical threshold
was observed at 30 minutes (Figure 1, 𝑃 < 0.01) and 1
hour (Figure 2, 𝑃 < 0.05) after administration, compared
with control group, respectively. From mechanical threshold
examined before daily administration on post-SNL day 4 to
day 6, gradual increase was observed, and it was significant
on post-SNL day 7 (Figure 3,𝑃 < 0.001) when comparedwith
control group.
3.3. BQ-123 Group at Dose of 25𝜇g. Higher trend of elevation
of mechanical threshold was demonstrated at dose of 25𝜇g
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Figure 3: Comparison of mechanical threshold between BQ-123
treatment groups (15𝜇g, 20𝜇g, 25𝜇g, and 30 𝜇g) and control group
30minutes before intrathecal administration. Assessment wasmade
on day 7 that no drug was administered. Data presented as mean ±
S.E.M and 𝑛 = 6/group. Significance is presented as ∧𝑃 < 0.05 for
BQ-123 15 𝜇g group versus control group; ∗∗∗𝑃 < 0.001 for BQ-123
20 𝜇g group versus control group; ###𝑃 < 0.001 for BQ-123 25 𝜇g
group versus control group; +++𝑃 < 0.001 for BQ-123 30𝜇g group
versus control group. SNL: sciatic nerve ligation.
throughout the time course of experiment, compared with
that at doses of 15𝜇g and 20𝜇g. On day 4, significant anti-
allodynic effect was observed at 30 minutes (Figure 1, 𝑃 <
0.05) but not 1 hour (Figure 2) after intrathecal drug adminis-
trationwhen comparedwith control group. On day 5, BQ-123
produced significant increase inmechanical threshold at both
time points of 30 minutes (Figure 1, 𝑃 < 0.001) and 1 hour
(Figure 2, 𝑃 < 0.05) after drug administration, compared
with control group. Similar trends were also observed on day
6 where significance of 𝑃 < 0.001 and 𝑃 < 0.01 was found,
at 30 minutes and 1 hour after intrathecal administration
compared to control group, respectively (Figures 1 and 2).The
antiallodynic effect of BQ-123 on post-SNL day 7 was shown
in Figure 3, and the effect was significant compared to control
group (𝑃 < 0.001).
3.4. BQ-123 Group at Dose of 30 𝜇g. BQ-123 at dose of
30 𝜇g achieved the most significant effect in amelioration of
mechanical allodynia throughout the study period. Signifi-
cant elevation of mechanical threshold was shown from day
4 to day 6 at 30 minutes after drug administration compared
to control group (Figure 1, all 𝑃 < 0.001). In Figure 2, anti-
allodynic effect was shown to remain significant 1 hour after
drug administration on day 4 (𝑃 < 0.01) and days 5 and
6 (both 𝑃 < 0.001) compared to control group. At the
preinjection time points, BQ-123 at dose of 30𝜇g showed
the greatest increase in mechanical threshold among other
dosages from post-SNL day 5. The threshold peaked signifi-
cantly on post-SNL day 7 when compared with control group
(Figure 3, 𝑃 < 0.001).
4. Discussion
Our results showed that daily intrathecal injections of ETAR
antagonist BQ-123 for 3 consecutive days from day 4 to day
6 after SNL alleviated mechanical allodynia with maximum
effect achieved at dose of 30 𝜇g in SNL neuropathic pain
model. To date, this is the first study to examine the effect of
ETAR antagonist in the CNS on the development of SNL-
induced neuropathic pain.
The SNL model is currently one of the classic neuro-
pathic pain models that produces spontaneous hind paw
nociception, hyperalgesia, and pronounced mechanical allo-
dynia [18]. Previous studies using this model showed that
mechanical threshold reached the lowest point about a week
after surgery and remained stable for up to 20 weeks [22–27].
Therefore, to investigate the influence of ETAR antagonist in
the CNS on the development of mechanical allodynia, one of
the major symptoms of neuropathic pain, we evaluated ani-
mal’s mechanical withdrawal threshold within a week after
SNL.
ET-1 has been suggested to modulate pathological pain
processing by the differential regulation of its receptors—
ETAR or ETBR [28–30]. The role of ET-1 and its receptors in
nociception and pathological pain has been described exten-
sively in animal studies following the direct administration
of exogenous ET-1 peptide with or without pharmacological
interventions on ET receptor activities [13–17, 31–33]. How-
ever, only few studies of ET-1 in neuropathic pain were done
in intact animal models which all focused in periphery [30].
Amongst these studies, one pointed out that ETAR was
mainly involved in neuropathic pain at the injury site induced
by chronic constriction injury (CCI) of sciatic nerve [17]. As
central sensitization is a major mechanism involved in the
development of neuropathic pain, therefore we were inter-
ested in exploring the effect of endogenous central ET-1
on SNL-induced neuropathic pain. Although ET-1 has been
shown to be analgesic in the CNS when administered in a
bolus [34], this result may not indicate the effect of innate ET-
1 in pain processing because the exogenous dose is an extra
boost to the CNS that it is abnormal to the system. In fact, a
previous study showed that systemic administration of ETAR
antagonist attenuated tactile allodynia in diabetic neuro-
pathic pain, suggesting that the interaction between endoge-
nous ET-1 and ETAR contributes to pain sensitization [16].
Therefore, by only antagonizing ETAR in the CNS, we may
know how endogenous ET-1 is involved in central pain pro-
cessing during the development of neuropathic pain. From
the BQ-123 groups with different dosages (15𝜇g, 20𝜇g, 25 𝜇g,
and 30 𝜇g), we found that drug group with higher dosage
showed higher trend of elevation in mechanical threshold.
Through the time course of tactile sensitivity changes in ani-
mals after treatment of BQ-123, we observed similar elevated
trends in mechanical threshold at both 30 minutes and 1
hour following injection, showing dose-dependent tendency.
The present result implies that normal interactions between
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ET-1 and ETAR contribute to pain sensitization in neuro-
pathic pain. This provides a new insight into the current
thoughts that ET-1 is antinociceptive in the CNS. We spec-
ulate that the level of ET-1 in the CNS may affect its actions
on its receptors differently in pain modulation because the
injected bolus of ET-1 produced analgesic effect as shown in
previous studies [8, 14] while the endogenous level of ET-
1 in the CNS did not exhibit such effect under pathological
condition in our study because ETAR antagonist reduced
pain sensation.
The effect of the drug also seemed to accumulate slowly
over the 3 days of once-per-day drug administration because
the mechanical threshold of the drug groups started to
increase and peaked on post-SNL day 7. This evidence sup-
ports the involvement of ET-1 in central sensitization as sug-
gested by a previous study [35], and this action is mediated
possibly via ETAR since prior exposure to its blockage
increased mechanical threshold gradually. This gradual rise
in mechanical threshold was noticeable every day after prior-
day exposure, but the change was not significant until day 7
which can be due to the fact that the mechanical threshold
of the drug groups reached its highest point while that of the
control group was further decreased on that day. This obser-
vation implies that repeated blockage of ETAR improves the
progression of the development of neuropathic pain. Taken
together, present results provide a new aspect that repeated
central administration of ETAR antagonist may be effective
in improving mechanical allodynia during the development
of neuropathic pain.
In addition, since higher dosage produced more signif-
icant effect in alleviating mechanical allodynia, the result
again supports our hypothesis that ET-1 modulates neuro-
pathic pain development partially via ETAR in the CNS. In
the present study, the highest BQ-123 concentration, 30 𝜇g,
elicited the greatest increase in the threshold and produced
the most significant improvement among the four given
dosages throughout the period of experiment. Although the
effects of the other three drug groups fluctuated at some time
points, they still showed increasing trends and significant
elevation of mechanical threshold near the end of the experi-
ment days (post-SNL day 7). The given dosages in these drug
groups were not enough to maintain a constant significant
effect but were still able to elevate themechanical pain thresh-
old to a certain degree after repeated administration. Our
result is similar to the situation in the periphery where ETAR
antagonist was found to reverse mechanical allodynia while
the ETBR antagonist did not [17]. These facts together sug-
gest that ET-1 contributes to both peripheral and central sen-
sitization via ETAR in neuropathic pain states. This is inter-
esting compared to a documented mechanism of ET-1 where
it was found to induce pain mainly through ETBR in the
periphery and central inflammatory pain [12, 14, 36], suggest-
ing that more than onemechanism is involved inmodulation
of central pain processing by ET-1.
In conclusion, our study demonstrated that repeated
central administration of BQ-123 could alleviate mechanical
allodynia during the development of SNL-induced neuro-
pathic pain. Higher dosage (30𝜇g) of BQ-123 could also
induce more stable and significant increase in pain threshold
in SNL-induced neuropathic pain.These observed behaviour
alterations contribute a new insight to the current roles of
ET-1 in pain modulation and potentially provide important
information for future studies in searching putative pharma-
cological intervention, including timing, for prevention and
treatment of neuropathic pain.
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